Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Fat oxidation is impaired during exercise in lipin-1 deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Declining malformation rates with changed antiepileptic drug prescribing: An observational study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  4. Clinical spectrum of STX1B-related epileptic disorders

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Electromagnetic source imaging in presurgical workup of patients with epilepsy: A prospective study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Evidence for oestrogen sensitivity in perinatal depression: pharmacological sex hormone manipulation study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Diagnostic value of oligoclonal bands in children: A Nationwide Population-Based Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Domain-specific cognitive dysfunction after cardiac surgery. A secondary analysis of a randomized trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Genome-wide gene expression in a pharmacological hormonal transition model and its relation to depressive symptoms

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Disease activity is highly variable in patients with multiple sclerosis (MS), both untreated and during interferon (IFN)-beta therapy. Breakthrough disease is often regarded as treatment failure; however, apart from neutralizing antibodies (NAbs), no blood biomarkers have been established as reliable indicators of treatment response, despite substantial, biologically measurable effects. We studied the biologic response to treatment in a cohort of NAb-negative patients to test whether difference in responsiveness could segregate patients with and without breakthrough disease during therapy.
Original languageEnglish
JournalNeurology
Volume74
Issue number18
Pages (from-to)1455-62
Number of pages8
DOIs
Publication statusPublished - 4 May 2010

ID: 31029944